Exponential advances in biotechnology, neurophysiology, molecular biology, radiology, and functional neurosurgery are rapidly being translated into therapies for chronic, debilitating neurologic conditions. Therapies include neural transplantation (including xenografts) for movement disorders (see Barker & Dunnett, 1999; and Wilkinson & Tröster, 1998) , genetic engineering to introduce genes encoding for neurotrophic factors, proteins, and neurotransmitter enzymes into the CNS (see Doering, 1996; Sapolsky & Steinberg, 1999; and Thompson, Lunsford, & Kondziolka, 1999) , and the development of neurotrophic electrodes connecting brain to computers that can act as communication ''prostheses'' (Kennedy & Bakay, 1998) . The recent finding that the human hippocampus may retain in adulthood its ability to generate neurons (Eriksson et al., 1998) raises the possibility that neural progenitor and stem cells (i.e., cells capable of differentiating into neurons and glia) may come to be used as transplants in Alzheimer's disease. Indeed, the next millennium will likely witness the scrutiny of novel therapies in patients with neurodegenerative conditions whose primary feature is a cognitive deterioration.
A logical consequence of such therapeutic trials for neuropsychology is the need for a transition from secondary to primary outcome measures. While cognitive rating scales and screening measures are already used in drug trials, the psychometric and conceptual limitations of such measures are probably as widely appreciated as are their economic advantages. I argue here that clinical neuropsychology will have to take at least three steps if it is to become a viable partner in functional neurosurgery and restorative neurology
